CGPM The 2020 00 ' 05-25

The First International Conference on "Green" Polymer Materials 05–25 NOVEMBER 2020 | ONLINE

Chaired by PROF. DR. ANTONIO PIZZI and PROF. DR. FRANK WIESBROCK

💥 polymers



Georgia Michailidou ^{1,*}, Nina-Maria Ainali ¹, Eleftheria Xanthopoulou ¹, Dimitrios N. Bikiaris ¹

¹ Department of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124, Thessaloniki, Greece. * Corresponding author: <u>gmichailid@chem.auth.gr</u>

A

ARISTOTLE UNIVERSITY OF THESSALONIKI





Abstract



- <u>Chronic obstructive pulmonary disease</u> (COPD) is associated with an enhanced chronic inflammation of the airways <u>caused by</u> tobacco smoking, air pollution or genetic factors
- **Fluticasone propionate** (FLU): corticosteroid with high topical activity
- **Salmeterol xinafoate** (SX): long-acting selective β_2 -adrenoceptor agonist
- FLU and SX
 - \checkmark Used in COPD treatment
 - × High degree of crystallinity, hydrophobic compounds.
- Inclusion of SX, FLU in polymeric microparticles results their amorphization
- <u>Chitosan</u>, a natural polysaccharide, along with its derivatives have been used for the inclusion of various pharmaceutical compounds in nano- and microparticles

Keywords: chitosan microparticles; modified chitosan; salmeterol xinafoate; fluticasone propionate; chronic obstructive pulmonary disease;



Experimental

→ Modification of CS with 2-hydroxyethyl acrylate (2-HEA) through a free radical reaction



→ Encapsulation of Salmeterol Xinafoate (SX) and Fluticasone propionate (FLU) in CS-g-PHEA microparticles through <u>ionic gelation technique</u>. FLU and SX (Fig. 1 *a, b)* were simultaneously enclosed in their interior in 10, 20 and 30% ratios.





Results & Discussion



SX microparticles

Inclusion of FLU and SX in CS-g-PHEA microparticles affects the crystallinity of the drugs leading to their **amorphization** (Fig. 3).



Fig. 3. XRD of FLU, SX, CS-g-PHEA-TPP-FLU-SX microparticles



<u>C</u>GPM

2020

Results & Discussion

Fig. 4. SEM images CS-g-PHEA-TPP-FLU-SX microparticles (a) 10%, (b) 20%, (c) 30%







Table. 1. Size (nm) of CS-g-HEA- FLU-SX microparticles

Sample	Z- Average (d.nm)	Zeta Potential (mV)
CS-g-PHEA-TPP- 10% FLU/SX	754	+26.7
CS-g-PHEA-TPP- 20% FLU/SX	1005	+22.6
CS-g-PHEA-TPP- 30% FLU/SX	2216	+26.6

Fig4. (a-c) and Table1.confirmthesuccessfulpreparationofsphericalshapedindividualmicro-scaled particles



Results & Discussion



FLU from CS-g-PHEA microparticles



- **In vitro** dissolution test of CS-g-PHEA microparticles in simulated body fluids (Fig 5 and 6).
- ✓ **Sustained release** of SX and FLU
- ✓ Enhancement of FLU and SX release up to 35 % and 40 % respectively

CGPM 2020



Conclusions

- ✓ <u>Modified chitosan nanoparticles were synthesized</u> and FLU and SX were successfully incorporated in their interior.
- ✓ FT-IR spectroscopy evaluated the CS-g-PHEA-FLU-SX interactions, confirm a *successful inclusion*.
- ✓ XRD analysis showed the *amorphization of FLU and SX* into the nanoparticles.
- ✓ The prepared nanoparticles were of <u>spherical shape</u>, in micro scale.
- ✓ <u>Sustained</u> and <u>enhanced release</u> of SX and FLU was achieved



Acknowledgments

ARISTOTLE UNIVERSITY OF THESSALONIKI BIKIARIS LAB Faculty of Sciences, Department of Chemistry

The author wishes to acknowledge co-funding of this research by European Union-European Regional Development Fund and Greek Ministry of Education, Research and Religions/EYDE-ETAK through program EPANEK 2014-2020/Action "EREVNO-DIMIOURGO-KAINOTOMO" (project T1E Δ K-02667).





European Regional Development Fund avánτυξη - εργασία - αλληλεγγύη Partnership Agreement 2014 - 2020



Supplementary Materials

<u>Full text paper</u>: *https://www.mdpi.com/1420-3049/25/17/3888/htm*

Contact Info *in https://www.linkedin.com/in/georgia-michailidou-b29699193/*

R⁶ https://www.researchgate.net/profile/Georgia_Michailidou3

